Presentation is loading. Please wait.

Presentation is loading. Please wait.

Pneumonectomy is a valuable treatment option after neoadjuvant therapy for stage III non–small-cell lung cancer  Walter Weder, MD, Stéphane Collaud, MD,

Published byVladka Erić Modified over 5 years ago

Similar presentations

Presentation on theme: "Pneumonectomy is a valuable treatment option after neoadjuvant therapy for stage III non–small-cell lung cancer  Walter Weder, MD, Stéphane Collaud, MD,"— Presentation transcript:

1 Pneumonectomy is a valuable treatment option after neoadjuvant therapy for stage III non–small-cell lung cancer  Walter Weder, MD, Stéphane Collaud, MD, Wilfried E.E. Eberhardt, MD, Sven Hillinger, MD, Stefan Welter, MD, Rolf Stahel, MD, Georgios Stamatis, MD  The Journal of Thoracic and Cardiovascular Surgery  Volume 139, Issue 6, Pages (June 2010) DOI: /j.jtcvs Copyright © Terms and Conditions

2 Figure 1 Response to induction therapy.
The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /j.jtcvs ) Copyright © Terms and Conditions

3 Figure 2 Overall survival after induction therapy and pneumonectomy for NSCLC. The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /j.jtcvs ) Copyright © Terms and Conditions

4 Figure 3 Survivals for locally advanced preinduction clinical stages IIIA and IIIB NSCLC. The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /j.jtcvs ) Copyright © Terms and Conditions

5 Figure 4 Survival for preinduction clinical stages IIIA and IIIB, according to their T and N status. The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /j.jtcvs ) Copyright © Terms and Conditions

6 Figure 5 Stage-related survival after induction therapy and pneumonectomy for NSCLC. The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /j.jtcvs ) Copyright © Terms and Conditions

Download ppt "Pneumonectomy is a valuable treatment option after neoadjuvant therapy for stage III non–small-cell lung cancer  Walter Weder, MD, Stéphane Collaud, MD,"

Similar presentations

Pathologic N1 non-small cell lung cancer: Correlation between pattern of lymphatic spread and prognosis Alessandro Marra, MD, PhD, Ludger Hillejan, MD,

Pathologic N1 non-small cell lung cancer: Correlation between pattern of lymphatic spread and prognosis Alessandro Marra, MD, PhD, Ludger Hillejan, MD,
Size matters: A comparison of T1 and T2 peripheral non–small-cell lung cancers treated with stereotactic body radiation therapy (SBRT)  Neal E. Dunlap,

Size matters: A comparison of T1 and T2 peripheral non–small-cell lung cancers treated with stereotactic body radiation therapy (SBRT)  Neal E. Dunlap,
Lost in translation The Journal of Thoracic and Cardiovascular Surgery

Lost in translation The Journal of Thoracic and Cardiovascular Surgery
Stephen R. Broderick, MD, MPHS 

Stephen R. Broderick, MD, MPHS 
The eighth edition TNM stage classification for lung cancer: What does it mean on main street?  Frank C. Detterbeck, MD  The Journal of Thoracic and Cardiovascular.

The eighth edition TNM stage classification for lung cancer: What does it mean on main street?  Frank C. Detterbeck, MD  The Journal of Thoracic and Cardiovascular.
Characteristics and outcomes of secondary nodules identified on initial computed tomography scan for patients undergoing resection for primary non–small.

Characteristics and outcomes of secondary nodules identified on initial computed tomography scan for patients undergoing resection for primary non–small.
One in every 14 patients with early-stage lung cancer is not being treated!  Benny Weksler, MD, MBA  The Journal of Thoracic and Cardiovascular Surgery 

One in every 14 patients with early-stage lung cancer is not being treated!  Benny Weksler, MD, MBA  The Journal of Thoracic and Cardiovascular Surgery 
It is not just about surgery versus stereotactic ablative radiotherapy, it is about curing as many patients with lung cancer as possible  Alessandro Brunelli,

It is not just about surgery versus stereotactic ablative radiotherapy, it is about curing as many patients with lung cancer as possible  Alessandro Brunelli,
Effect of tumor size on prognosis in patients with non–small cell lung cancer: The role of segmentectomy as a type of lesser resection  Morihito Okada,

Effect of tumor size on prognosis in patients with non–small cell lung cancer: The role of segmentectomy as a type of lesser resection  Morihito Okada,
Lung cancer screening: No more excuses

Lung cancer screening: No more excuses
Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 
Outcomes of unexpected pathologic N1 and N2 disease after video-assisted thoracic surgery lobectomy for clinical stage I non–small cell lung cancer  Hong.

Outcomes of unexpected pathologic N1 and N2 disease after video-assisted thoracic surgery lobectomy for clinical stage I non–small cell lung cancer  Hong.
Ground glass opacity of the lung: The veil that needs lifting

Ground glass opacity of the lung: The veil that needs lifting
Survival after resection of synchronous non–small cell lung cancer

Survival after resection of synchronous non–small cell lung cancer
Brian N. Arnold, MD, Daniel C. Thomas, MD, MPH, Joshua E

Brian N. Arnold, MD, Daniel C. Thomas, MD, MPH, Joshua E
An analysis, systematic review, and meta-analysis of the perioperative mortality after neoadjuvant therapy and pneumonectomy for non–small cell lung cancer 

An analysis, systematic review, and meta-analysis of the perioperative mortality after neoadjuvant therapy and pneumonectomy for non–small cell lung cancer 
Joshua E. Rosen, BASc, Michelle C

Joshua E. Rosen, BASc, Michelle C
John M. Varlotto, MD, Abram Recht, MD, John C. Flickinger, MD, Laura N

John M. Varlotto, MD, Abram Recht, MD, John C. Flickinger, MD, Laura N
The Influence of the Evolution of First-Line Chemotherapy on Steadily Improving Survival in Advanced Non-Small-Cell Lung Cancer Clinical Trials  Krista.

The Influence of the Evolution of First-Line Chemotherapy on Steadily Improving Survival in Advanced Non-Small-Cell Lung Cancer Clinical Trials  Krista.
Patterns of survival and recurrence after surgical treatment of early stage non–small cell lung carcinoma in the ACOSOG Z0030 (ALLIANCE) trial  Stacey.

Patterns of survival and recurrence after surgical treatment of early stage non–small cell lung carcinoma in the ACOSOG Z0030 (ALLIANCE) trial  Stacey.

Similar presentations

Ads by Google